Side effects of sugammadex use in pediatric patients

Sarı, Sinem; Taşdemir, Banu; Özkisacik, Sezen; Gürsoy, Feray

doi:10.5799/ahinjs.01.2013.03.0281

Cited by 5 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Sari et al conducted a retrospective study of 46 pediatric patients (aged between 28 days and 17 years) who received sugammadex (2 mg/kg) to reverse rocuronium blockade (0.6 mg/kg) in anesthetized patients within their institution. 167 No hypersensitivity or statistically side-effects correlated to sugammadex were observed. Further safety studies are warranted.…”

Section: Safetymentioning

confidence: 99%

Safety and Efficacy of Sugammadex for Neuromuscular Blockade Reversal

Lobaz

Clymer

Sammut

2014

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

AbstrAct:Since its first human use in 2005, the γ-cyclodextrin sugammadex (Org 25969) has had the potential to become the reversal agent of choice, for rocuronium-or vecuronium-induced neuromuscular blockade. Sugammadex binds to the aminosteroid neuromuscular blocker, encapsulating it and extracting it from the neuromuscular junction, effectively ceasing activity and allowing neuromuscular transmission to recover rapidly. Phases I-III and subsequent trials have found sugammadex to be safe and effective in a wide range of doses and for the reversal of a range of depth of muscle relaxation in healthy volunteers and a variety of disease states. Sugammadex use may allow refinement of anesthetic practice and improvement in surgical conditions, through the maintenance of deep neuromuscular blockade right to the end of surgery, with subsequent rapid reversal. Debate remains about the use of sugammadex in the treatment of rocuronium anaphylaxis and airway emergencies. The high price of sugammadex currently prohibits its routine use, but if the price falls, after expiry of its patent, it may become cost-effective as a readily available agent in certain specific clinical situations. Serious adverse reactions have occurred in less than 1% of patients and are most commonly because of hypersensitivity. No deaths have been reported, but caution is advised in neonates, pediatrics, and pregnancy where data are lacking.

show abstract

Section: Safetymentioning

confidence: 99%

Safety and Efficacy of Sugammadex for Neuromuscular Blockade Reversal

Lobaz

Clymer

Sammut

2014

Clinical Medicine Insights: Therapeutics

View full text Add to dashboard Cite

show abstract

“…Another controversial group in the use of sugammadex is nursing mothers and newborns. Due to insufficient evidence, the use of sugammadex in newborns is still not recommended (Bridion® (sugammadex), 2015; Munro et al, 2019; Sarı et al, 2013; Satomoto et al, 2016).…”

Section: Introductionmentioning

confidence: 99%

Effect of sugammadex administration on neural tube development in 48‐h chick embryos

Büyükerkmen,

Atay,

Firat

et al. 2023

Microscopy Res & Technique

View full text Add to dashboard Cite

Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. The aim of this study is to investigate the teratogenic effects of sugammadex on neural tube and embryonic development in early chick embryos. In this study, 50 0‐day fertile specific non‐pathogenic (SPF) eggs were used. Fifty eggs were divided into 5 different groups, each consisting of 10 pieces. While no substance was given to the control group at the 28th hour of the study, 4 different doses of sugammadex were administered to the experimental groups, respectively 2, 4, 8, 16 mg/kg. Cranio‐caudal lengths of embryos, somite numbers, average number of argyrophilic nucleolar regulatory regions (AgNOR) per nucleus, total AgNOR area/total nuclear area (TAA/NA) ratios, Caspase‐3 H‐Score results, and presence of neural tube defect were compared among the groups. While the mean cranio‐caudal lengths, somite counts, TAA/NA ratios and AgNOR counts of the embryos were found to be statistically significantly lower than the control group, Caspase‐3 H‐Score mean results were found to be significantly higher (p < .05). In addition, it was observed that there was an increase in neural tube patency and developmental delay. As a result, sugammadex crossing the placenta was revealed to increase the release of proapopitotic molecules and disrupt the developmental stages of embryos. Thus, it was determined that sugammadex in increased developmental delay and incidence of neural tube defects in early chick embryos with increased dose dependent. Despite these results, the effects of sugammadex on fetal development in in vivo and in vitro environments should be studied with further studies.Research Highlights Sugammadex is a new generation drug that has led to significant changes in the practice of anesthesia. However, its effects on fetal development are not yet fully known. It has been observed that different doses of sugammadex increase the risk of neural tube defect development on chick embryos and slow the embryo development in a dose‐dependent manner.

show abstract